Holen Sie sich die Stockscreener-App
78.50
0.00%
0.00
Schlusskurs vom Vortag:
$78.50
Offen:
$79.66
24-Stunden-Volumen:
1.43M
Relative Volume:
1.80
Marktkapitalisierung:
$4.31B
Einnahmen:
$1.43B
Nettoeinkommen (Verlust:
$107.13M
KGV:
40.52
EPS:
1.9372
Netto-Cashflow:
$161.04M
1W Leistung:
-1.80%
1M Leistung:
+8.68%
6M Leistung:
+26.45%
1J Leistung:
+73.79%
1-Tages-Spanne:
$77.71
$80.45
1-Wochen-Bereich:
$77.71
$80.95
52-Wochen-Spanne:
$41.02
$80.95
Livanova Plc Stock (LIVN) Company Profile
Firmenname
Livanova Plc
Sektor
Branche
Telefon
4402033250662
Adresse
20 EASTBOURNE TERRACE, LONDON
Compare LIVN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
78.50 | 4.31B | 1.43B | 107.13M | 161.04M | 1.9372 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-20 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Eingeleitet | Goldman | Buy |
| 2024-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Bestätigt | Needham | Buy |
| 2024-02-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-02-24 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-03 | Eingeleitet | Goldman | Buy |
| 2021-08-20 | Bestätigt | Needham | Buy |
| 2021-07-20 | Hochstufung | Needham | Hold → Buy |
| 2021-03-03 | Herabstufung | Berenberg | Buy → Hold |
| 2021-01-05 | Herabstufung | Needham | Buy → Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-26 | Bestätigt | Needham | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-08 | Eingeleitet | Stifel | Buy |
| 2018-05-31 | Bestätigt | Needham | Buy |
| 2018-02-28 | Bestätigt | Needham | Buy |
Alle ansehen
Livanova Plc Aktie (LIVN) Neueste Nachrichten
LIVN SEC FilingsLivanova Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Jette Nygaard-Andersen joins LivaNova board as a new director - MSN
LivaNova demonstrates 84.5% cumulative response rate with PolySync programming in OSPREY study for obstructive sleep apnea - MSN
LivaNova reports improved OSA outcomes with PolySync programming - MSN
LivaNova PLC (LIVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LivaNova PLC (LIVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LivaNova PLC (LIVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LivaNova PLC (LIVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LivaNova PLC (LIVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
LivaNova PLC (LIVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LivaNova PLC (LIVN) Institutional Confidence - TradingKey
LivaNova (LIVN) director logs RSU vesting, tax withholding and new 2027 RSU grant - Stock Titan
[Form 4] LivaNova PLC Insider Trading Activity - Stock Titan
LivaNova PLC (LIVN) director trades shares, receives 2,383 new RSUs - Stock Titan
LivaNova (LIVN) director logs RSU vesting, tax withholding and new grant - Stock Titan
LivaNova (LIVN) director reports RSU vesting, tax withholding and new grant - Stock Titan
LivaNova (LIVN) officer vests RSUs as 1,032 shares withheld for tax - Stock Titan
LivaNova (LIVN) director Jette Nygaard-Andersen receives 2,383 RSU grant - Stock Titan
LivaNova (LIVN) director settles RSUs, withholds shares for taxes and receives new RSU grant - Stock Titan
LivaNova (LIVN) director logs RSU vesting, tax withholding and 2027 grant - Stock Titan
LivaNova (LIVN) director Story Brooke reports RSU vesting, tax withholding and new grant - Stock Titan
LivaNova (LIVN) director logs RSU vesting, tax withholding and new 2027 grant - Stock Titan
LivaNova Reports Improved OSA Outcomes With PolySync Programming - Yahoo Finance
LivaNova’s programming algorithm boosts response rates in sleep apnoea patients - Medical Device Network
LivaNova (LIVN) Reports Promising Outcomes for Sleep Apnea Treat - GuruFocus
LivaNova sleep apnea therapy shows 84.5% response rate with new algorithm - Investing.com
LIVANOVA reports 84.5% response rate with PolySync in sleep apnea study - StreetInsider
(LIVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
LivaNova PLC (LIVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LivaNova PLC (NASDAQ: LIVN) insider sells 1,800 shares for $136,350 - Stock Titan
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea - Business Wire
Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook? - simplywall.st
Jette Nygaard-Andersen named director of LivaNova board - Medical Buyer
LivaNova (LIVN) Stock Valuation Check After Strong Recent Shareholder Returns - Yahoo Finance
LivaNova to present at Goldman Sachs Global Healthcare Conference in June - MSN
LivaNova adds Jette Nygaard-Andersen to board of directors - Investing.com UK
LivaNova adds Jette Nygaard-Andersen to board of directors By Investing.com - Investing.com Australia
Jette Nygaard-Andersen Joins LivaNova Board as a New Director - The Joplin Globe
LivaNova PLC Announces Board and Committee Changes - marketscreener.com
LivaNova (NASDAQ: LIVN) director Jette Nygaard-Andersen reports zero common stock on Form 3 - Stock Titan
LivaNova (NASDAQ: LIVN) AGM backs directors, pay and buyback powers - Stock Titan
LivaNova Stock: My Targets Hold, Maintaining My Rating For 2H26 (NASDAQ:LIVN) - Seeking Alpha
LivaNova stock hits 52-week high at 76.92 USD - Investing.com
LivaNova stock hits 52-week high at 76.92 USD By Investing.com - Investing.com Nigeria
LivaNova PLC at Goldman Sachs Healthcare Conference Transcript - GuruFocus
LivaNova PLC (LIVN) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
LIVN: Improved VNS reimbursement and manufacturing scale drive growth, with OSA and new launches ahead - TradingView
LivaNova appoints Anne Liddy as chief legal officer - MSN
LivaNova beats estimates but shares fall 2% on guidance concerns - Investing.com
Earnings call transcript: LivaNova PLC beats Q1 2026 estimates, shares rise - Investing.com
LivaNova names Anne Liddy as chief legal officer By Investing.com - Investing.com Australia
Finanzdaten der Livanova Plc-Aktie (LIVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Livanova Plc-Aktie (LIVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCHERMERHORN TODD C | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
13,105 |
| Bianchi Francesco | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
11,270 |
| Bianchi Francesco | Director |
Jun 15 '26 |
Sale |
80.19 |
1,200 |
96,228 |
9,584 |
| PODLOGAR SUSAN M | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
6,128 |
| Barry James Christopher | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
8,404 |
| Tezel Ahmet | Chief Innovation Officer |
Jun 15 '26 |
Option Exercise |
0.00 |
2,965 |
0 |
7,122 |
| KOZY WILLIAM A | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
5,681 |
0 |
38,248 |
| Enxing Seng Stacy | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
15,793 |
| Story Brooke | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
4,042 |
0 |
10,274 |
| Zurbay Donald | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
2,560 |
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):